About
Technology
Issues
FAQ
Links
Official Page
From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.
![From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)](https://img.exaly.com/article-chart/40542113/citations/graph.svg)
